By Dr. Betty Martini, D.Hum.
Mission Possible International
9270 River Club Parkway
Duluth, Georgia 30097
Telephone: 770-242-2599
Web Site:

Posted: 13 October 2008

How aspartame gained approval in the US through the political chicanery of Don Rumsfeld is well known. Listen to Attorney Jim Turner explain how it was done. Searle who was the original manufacturer, knew the FDA wanted them indicted for fraud. Therefore it had to be approved in another country before they could rubber stamp it around the world. What to do! There was no chance of getting it approved if the history was known. On January 10, 1977 Richard Merrill recommended to U. S. Attorney Sam Skinner that a grand jury investigate Searle for "apparent violations of the Federal Food, Drug and Cosmetic Act 21 USC 331, (e), and the False Reports to the Government Act, 18 U.S.C.1001 for "their willful and knowing failure to make reports to the Food and Drug Administration required by the Act 21. U.S.C 355 (i) and for concealing material facts and making false statements to establish the safety of aspartame." The FDA calls special attention to studies investigating the effects of NutraSweet on monkeys and hamsters.

Aspartame was approved in England because G. D. Searle made a business deal with Paul Turner of the agency there. There was a big blowout in Parliament because of it but they didn't rescind the order. No studies were done in the UK. They relied on the U. S. FDA.

Who did the FDA rely on? On March 24, 1976 the FDA task force reported, "At the heart of the FDA's regulatory process is its ability to rely upon the integrity of the basic safety data submitted by sponsors of regulated products. Our investigation clearly demonstrates that, in the G. D. Searle Company, we have no basis for such reliance now." The Task force further says, "Some of our findings suggest an attitude of disregard for FDA's mission of protection of the public health by selectively reporting the results of studies in a manner which allays the concerns of questions of an FDA reviewer.

In a meeting with Food Standards in New Zealand last year it was finally admitted: "We relied on the FDA, no studies have been done here"? Clearly the FDA had to rely on studies reported to be "concealing material facts". Don Rumsfeld called in his "markers" to get it approved in the US. Yet, the aspartame manufacturers write "this is the most tested product in history" as consumers continue to become disabled or dying and the complaints never stop. As was reported in Congress, the FDA was so overwhelmed by the complaints from aspartame they actually referred the victims to the AIDS Hotline.

Read on below the famous Guardian article that exposed how aspartame became approved in England. Food Standards was setup to keep its distance from industry, yet this comment is made on Food Standards web site: . Monday 7 July 2008 "The Prime Minister has called for stronger partnerships between Government and the food services industry". Yet Food Standards was created specifically to distance the organization from the food services industry so decisions would be based on consumer safety and truth and not industry propaganda. The Food Standards web site is full of industry propaganda.

Dr. Betty Martini, D.Hum.
Founder, Mission Possible World Health International
9270 River Club Parkway
Duluth, Georgia 30097

Aspartame Toxicity Center:

Sweet Misery: A Poisoned World, aspartame documentary at or in the UK, Namaste Publishing -

Aspartame medical text: Aspartame Disease: An Ignored Epidemic, H. J. Roberts, M.D. & Excitotoxins: The Taste That Kills by neurosurgeon Russell Blaylock, M.D.,

February 13, l984, The Guardian

by Andrew Veltch Medical Correspondent (front page)

"Professor Paul Turner, head of the Government committee which approved the controversial artificial sweetener, aspartame, has an indirect link with its manufacturer, G. D. Searle.

Synthelabo, Searle's major partner in Europe, is behind the funding of Professor Turner's research at St. Bartholomew's Hospital in London.

Professor Turner told the Guardian on Friday: "The Department of Health and Social security are aware of any commercial relationships I have, including my relationship with Synthelabo and the Charterhouse Unit. These were declared several years ago."

His research is funded by a charity called the Synthelabo Foundation, which receives it money from a limited company called the Charterhouse Clinical Research Unit. The share capital for that company was provided by Lers, a subsidiary of Synthelabo.

Studies have shown that aspartame would seriously damage some children.

Page 4 continued:

The head of the Government committee responsible for approving the controversial new artificial sweetener aspartame - sold as Canderel and NutraSweet - has an indirect but significant link with the manufacturers, G. D. Searle.

A charity set up by Professor Paul Turner, chairman of the toxicity committee, to fund his research at St. Bartholomew's Hospital, London, is backed by Searle's biggest partner in Europe, Synthelabo.

Chairman and members of expert committees which examine potentially hazardous substances are obliged to declare their commercial interests when they are appointed, and in practice, before each meeting. Although Professor Turner's interest may not qualify as a "commercial interest," senior members of the medical establishment consider it to be in the public interest for such matters to be declared.

The junior health minister, Mr. John Patten, wrote in a letter during the parliamentary row over aspartame in October that Professor Turner had never had any connections with Searle.

Professor Turner's charity is the Synthelabo Foundation, of which he is one of two trustees. The other is the vice-president in charge of research at Synthelabo. Professor Guiseppe Bartholini.

Searle and Synthelabo, the fourth biggest drugs company in France, have set up three joint companies in the last two years --one, called Lorex, in the UK last year.

Four years ago a Synthelabo subsidiary, Lers, provided the share capital to set up a limited company to fund Professor Turner's charity, the company is called the Charterhouse Clinical Research Unit.

Professor Turner is a consultant to Charterhouse, whose chairman, Mr. Paul Barclay, is the English lawyer for the Synthelabo group. The Charterhouse medical director, Dr. Steven Warrington, is an honorary lecturer in Professor Turner's pharmacology department at St. Bartholomew's.

Mr. Patten said in a letter to the Labour MP, Mr. Dale Campbell-Savours, in October: "Professor Turner has never had any connections with Searle, nor has he or anyone in his department been funded by them."

Professor Turner told the Guardian: "The Department of Health and Social Security is aware of any commercial relationships I have, including my relationship with Synthelabo and the Charterhouse Unit. These were declared several years ago."

Both aspartame and the partnership with Synthelabo are considered essential to Searle's survival, according to City analysts.

When the l983 results are in, they are likely to show that Searle's operating profits from drugs have "plunged by as much as 75 per cent," while profits from aspartame may have "more than quadrupled," according to the US brokers, Kidder Peabody. Searle is expected to sell nearly $600 million worth of aspartame worldwide this year.

The decline in Searle's drug business has been caused by a lack of new products. The Synthelabo connection gives Searle access to high-grade European research. The first joint company was Lorex, set up in the United States in l982. Lorex has since formed a Canadian subsidiary. The other two joint companies were set up last year -- one in Holland, the other in the UK.

Synthelabo, based in Paris and owned by the beauty firm L'Oreal (which is itself owned by Nestle) was until a few years ago a medium-sized company investing heavily in research.

The Searle deals form what is thought to be the largest single sector of am ambitious expansion programme that has made it the fourth biggest drugs firm in France. The Searle connection has given Synthelabo the status of an international company, as well as a new outlets, for its producers. Itis in Synthelabo's interests to ensure that Searle thrives.

Professor Turner and his colleague. Dr. Warrington, have worked on the development of Synthelabo's beta blocker, Betazolo. They have published several papers on the drug in the British Journal of Clinical Pharmacology.

Charterhouse was heavily criticized last month for paying unemployed people and students 250 lbs or more to act as guinea pigs in the first trials of a cancer drug, which, it was feared might itself promote the growth of certain tumours.

Professor Turner told the Guardian in a statement last month that Charterhouse was an independent company. Mr Barclay, the Charterhouse chairman, explained: "It was setup by Lers (Synthelabo's research subsidiary), it was their idea, and they subscribed the initial share capital. In l981 most of their interest was transferred to the charity. It was a way of having a research facility in England for them and for other pharmaceutical companies."

Professor Turner also told the Guardian last month that "any profits" from Charterhouse went to his charity. According to the last accounts filed by Charterhouse, in l982 the firm paid 10,131 lbs "under covenant to the trustees of Synthelabo Foundation. After this payment was made, the firm recorded a profit of 40,464 lbs. In l981, Charterhouse paid 5,294 lbs to the trustees.

Mr. Barclay explained: "The taxable profits went to the charity. They are the profits upon which, if they had not been covenanted in this way, tax would have to be paid."

The charity's file at the Charity Commissioner contains only one set of accounts (for l983). They have not been audited. The trustees are required by the Commission t file accounts every year. According to the unaudited l983 accounts, the charity received 15,425 (lbs) under covenant from Charterhouse and gave St. Bartholomew's Medical College 21,206 (lbs).

The two trustees, Professor Turner and Professor Bartholini, of Synthelabo, are empowered according to the charity's records, to use the money to fund research into clinical pharmacology and allied fields, for education and "for the relief of sickness" not necessarily at St. Bartholomew's. The trustees may, if they wish, invest the money.

The Guardian asked Professor Turner if he had been aware of the Searle/Synthelabo connection, and if so whether he considered it might have influenced his views on the products. He was also asked if he agreed that people in positions such as his had an ethical duty to declare their interests. He did not answer.